induced murine fibrosarcoma system have been identified by subclass and protective capacity in adoptive syngeneic hosts. Lymph-node or spleen cells taken at weekly intervals after inoculation of syngeneic chemically induced fibrosarcomas were enriched by 3 methods in T, B, and "null" cell subclasses, and assayed for proliferative kinetics in response to soluble membrane antigens. The stimulated subpopulations were found to be heterogeneous, their composition varying with time and tumour burden. Initial proliferative responses after tumour inoculation were limited to the T-enriched subpopulation. Later during tumour growth, T, B and null cell fractions were vigorously and equally stimulated by tumour antigen. The ability of the same T, B or null-cell subpopulations to inhibit tumour growth was measured in adoptive hosts by a modified Winn assay. Only the T-cell subpopulation responding to tumour antigen in vitro effectively and consistently retarded tumour growth in vivo. In contrast to the shared specificities on syngeneic tumours identified by the proliferative assay, tumour-growth inhibition was limited to the specific tumour borne by the cell donor.
SOLUBLE TUMOUR ANTIGENS induce in vitro proliferation of lymphoid cells from various tumour-bearing hosts (Jehn et al., 1970; Gutterman et al., 1972; Meltzer et al., 1972; Mavligit et al., 1973; Vanky et al., 1974; Forbes et al., 1975; Gainor et al., 1976; Calderwood et al., 1977) . Reactivity to 3-methylcholanthrene-induced (MCA) fibrosarcoma antigens is identified first in cells taken from the regional lymph nodes, and is thereafter detected sequentially in peripheralblood lymphocytes, spleen, and nonregional nodes during the course of tumour growth. Time-course and doseresponse kinetic data of responses to various syngeneic tumours have suggested that both shared and nonshared specificities induce multiclonal proliferation (Forbes et al., 1975) .
In the experiments described here, lymphocyte subpopulations enriched for T and B subclasses were examined for responses to solubilized tumour antigens at intervals throughout the course of tumour-bearing. Tumour-growth inhibitory activity of each of these enriched subpopulations was concurrently assessed in adoptive syngeneic hosts. The data show that, while proliferation is stimu-lated in each subpopulation, only T cells at their peak of responsiveness in vitro inhibit tumour growth.
MATERIALS AND METHODS
Mice.-Age-matched 6-12-week-old female C57BL/6 mice obtained from The Jackson Laboratory, Bar Harbor, Maine, or reared in this laboratory from Jackson breeding stock, were used in all experiments.
Tumours.-Tumours were induced in mice by injecting 0 5 mg MCA in 0 1 olive oil i.m. in each thigh. Tumours arose in 12-16 weeks and are identified by initials followed by a number. Riesfeld's procedure (1971) as previously described (Forbes et al., 1975) . Soluble antigen prepared from a particular tumour is referred to by the tumour designation followed by the symbol [S] . In all experiments soluble antigens were prepared from tumours of the same in vivo passage number as the tumours the experimental animals were bearing. Antigens were stored for not longer than 4 weeks at 4°C. Selected antigens were tested in rabbits and found to be pyrogen-negative. In the text, "homologous" tumour antigens refers to the soluble preparation derived from the same tumour the experimental animals were bearing; "syngeneic" antigen refers to antigen prepared from other MCA-induced tumours raised in the same strain of mice. In vitro assay for tumour-antigen stimulation.-The culture method was described previously (Forbes et al., 1975; Adler et al., 1970a,b (Forbes et al., 1975; Calderwood, 1977; Calderwood et al., 1977 (Calderwood, 1977, p. 61 ).
Note that the background level of 3H-dT incorporation in tumour-bearing lymphoid cell populations is higher than that of normal cell populations, a consistent reflection of the tumour-associated lymphoid hyperplasia characteristic of these tumours (Konda et al., 1973) . A high degree of correlation had previously been shown between "spontaneous" and antigen-induced 3H-dT incorporation in tumour-bearing cell populations (Forbes et al., 1975) . For brevity, mean spontaneous incorporation was subtracted from mean antigen-induced levels, and results are presented as net ct/min for the peak response level of each dose-response titration.
Subpopulation enrichment technique8.-Complement-mediated cell lysis: Rabbit antimouse brain (RAMB) serum was prepared by the method of Golub (1971) , absorbed once or twice with 1 part washed mouse RBC to 2 parts serum, and used at a final dilution of 1:30. Goat anti-mouse Ig (anti-Ig), generously provided by Dr Rebecca Blackstock, was used at a final dilution of 1:15. The same pool of guinea-pig complement (C') obtained lyophilized from Microbiological Associates, Bethesda, M.D., and reconstituted to original serum volume with PRMI, was used in all experiments at a final dilution of 1: 30. Two x 108 spleen or LNC wvere incubated for 60 min at 37°C with the appropriate dilutions of RAMB or anti-Ig and C' in a final volume of 30 ml RPMI, then washed x 3 to remove dead cells. Null cells were prepared by sequential treatment with anti-Ig + C' then RAMB + C'. Surviving cells were counted and used.
Control experiments established the effectiveness and specificity of both goat anti-Ig and RAMB treatments. In standard cytotoxicity tests anti-Ig + C', diluted 1:15, consistently killed 30-40% normal spleen cells and < 5% normal thymocytes. Absorbed RAMB, diluted 1: 30, killed 30-40% normal spleen cells, 60-70% LNC, and 95-100% thymocytes. These cytotoxicity values are consistent with published data. Additive toxicity experiments demonstrated that RAMB and the more conventional AKR antiThy 1.1 killed the same set of cells (Calderwood, 1977, p. 53) .
The functional efficacy of complementmediated cell lysis was tested in each experiment by assaying the responses of the residual cell subpopulation to the B-and T-cell mitogens, LPS and PHA. Anti-Ig+C' treatment greatly increased 3H-dT incorporation by surviving cells in response to PHA; it reduced to low levels or eliminated responses to LPS. RAMB + C' treatment eliminated the PHA response of the surviving cells and increased that to LPS. The resultant data are included as examples of the results from each separation technique used.
Nylon-wool column separation: T-enriched spleen-cell fractions were eluted from nylonwool columns prepared in 12ml disposable syringe barrels by the method of Julius et al. (1973) . B-enriched fractions were harvested by rinsing the columns rapidly with warm medium, and then compressing the nylon wool with the syringe plunger. Collected cell fractions were pooled. The efficacy of this method of cell separation was assessed in each individual experiment in terms of function of the surviving cells, as above.
Anti-mouse immunoglobulin columns: The
IgG fraction of anti-Ig was coupled to cyanogen bromide-activated Sephadex G-200, prepared as columns and used to remove B cells by the method of Chess et al. (1974) . The purity of T-enriched subpopulations eluted by this method was tested as above.
Modified Winn assay.-A modification of the Winn procedure (1961) was used to test specific anti-tumour activity of lymphoid tissues or their subpopulations. Lymphocytes from spleen, lymph nodes, or lymphoid subpopulations from these organs were mixed in various ratios with freshly trypsinized washed tumour-cell suspensions and injected in a volume of 0 3 ml into one hind footpad of syngeneic mice which had been sublethally irradiated with 4 Gy delivered from an 80OCi 137Cs source at a rate of 10 Gy/min (Model M Gammator, Radiation Machinery Corporation, Parsippany, N.J. (Fig. 3) . By the week~b eginning of the 2nd week of tumour bearing, when the tumour mass was just palpable, whole-spleen cells responded, and the T-enriched fraction response was the greatest at every level of tumour antigen tested. T-depleted fractions were minimally responsive. At 3 weeks, the T-cell fraction was still active, but the B-enriched fraction was most active. and, as is shown, the proliferative response ere respond-was primarily in the T-enriched subpopunormal and lation. LNC (regional, and pooled regional growth, but were strong also in B-enriched and null cells after 3-4 weeks of tumour bearing. It was of interest to determine whether the in vitro behaviour of such subpopulations was associated with a capacity to retard tumour growth in vivo. Lymphocyte subpopulations were tested simultaneously for in vitro response to soluble tumour antigen and for in vivo capacity to inhibit tumour growth in an adoptive host.
The results of a representative experiment are shown in Table V . In this experiment spleen cells were taken at a time after tumour inoculation (2.5 weeks) when T-, B-and null-cell subpopulations all responded vigorously in vitro to tumour antigen. The spleen cells were fractionated by C'-mediated lysis, and surviving cell 36 subpopulations were tested with homologous antigen. Aliquots of the same subpopulations, mixed with viable homologous tumour cells at a 2000: 1 ratio, were inoculated into the right hind footpads of groups of 5 sublethally irradiated mice. Footpad measurements 22 days after inoculation showed that only the T-cell subpopulations inhibited tumour growth. At this time, most animals from the T-cell group were still tumour-free. Unfractionated tumour-bearing spleen cells retarded tumour growth slightly. Control cells were ineffective.
Similar experiments demonstrated that tumour-bearing lymphocytes best retarded tumour growth in adoptive hosts if taken 1-5-2-5 weeks after tumour inoculation, when the proliferation by the T- (Fig. 5) . Since inhibited tumour growth appreciably in the response to soluble antigens from adoptive hosts. This anti-tumour activity syngeneic tumours was shared or cross-was maximal during the peak of T-cell reactive in the in vitro assay (Forbes et The cell separation techniques used here tumour bearing. Only LNC regional to made possible the isolation of lymphoid the homologous tumour retarded tumour cell subpopulations at the peak of their growth, and this activity was maximal at in vitro responsiveness to tumour-asso-2 weeks, as before. In the experiment ciated antigens. Even though no single shown in Fig. 7 , T cells from normal technique of T-or B-cell purification lymph nodes or lymph nodes regional to yields subpopulations completely free PC8 or PCI tumour were collected after from other cell classes or macrophages, the data from all 3 enrichment techniques used here were totally congruent. Operationally, preselection by C'-mediated lysis provided the most convenient and effective method of deriving relatively pure subpopulations, as judged by functional responses to mitogens.
The importance of T cells to tumour rejection in other tumour systems is well known (Kearney et al., 1975; Bernstein et al., 1976) . T-cell inhibition of homologous tumour growth in adoptive hosts, shown here for chemically induced sarcomas, occurs early in tumour bearing, when the in vitro proliferative responses are chiefly T-cell mediated. This is consistent with the proposition that early T-cell proliferation, as revealed in the in vitro assay, reflects the generation of a subset of tumour-specific T cells directed toward TSTA, as well as subsets which are crossreactive with, or share antigens with, syngeneic tumours.
Old et al. (1962) found that peritonealexudate cells (PEC) gave singular inhibition of tumour growth in the adoptive host, but LN or spleen cells from the same hosts had no effect. Their experiments did not involve purified cell subpopulations, or explore the early phase of tumour bearing described here.
We have also found (Smith et al., 1978; Chauvenet & Smith, 1979 ) that a high degree of growth inhibition is afforded by peritoneal-exudate cells in the adoptivetransfer technique described here. Such inhibition was clearly T-cell mediated. Moreover, long-term-cloned T-cell lines which show cytotoxicity in vitro and growth inhibition in vivo for homologous tumour can be derived from the same PEC populations (Smith et al., 1980) . The data reported here, taken with earlier studies, suggest strongly that tumour-specific T cells are generated early by proliferation in response to tumour presence, and that T-cell-mediated inhibition of growth of chemically induced sarcomas is primarily directed toward an antigenic system or systems not shared with other syngeneic tumours. A corollary of this conclusion is that antigen-responsive T cells not protective in vivo are generated at the same time, and that these subsets respond to specificities shared with syngeneic tumours. These experiments emphasize also that tumour-antigen-associated proliferation stimulated by chemically induced sarcomas also occurs in B-enriched subpopulations and a large subpopulation of null cells, chiefly occurring later in tumour bearing. Neither of these subpopulations inhibits tumour growth in an adoptive host.
